Elevance Health, Inc. has reported a rise in its benefit expense ratio to 86.8%, up from 86.4% the previous year, highlighting financial pressures even as it maintains a strong market cap of $86.15 billion. During a recent annual meeting, shareholders elected three directors and approved an executive compensation program, albeit on an advisory basis. The company also faced governance hurdles, notably rejecting a proposal for an independent study on political contributions, as it adapts to evolving market dynamics with a current share price of $390.
“Elevance Health · benefit expense ratio increased · 86.8% · from 86.4% last year”
“Elevance Health · experienced · benefit expense ratio · 86.8%”
“Elevance Health · is a · company · true”
“Elevance Health Inc. · has a market cap of · $86.15B · true”
“Elevance Health · is a · company · true”
“Elevance Health · is a · company · true”
“Elevance Health shareholders · held · annual meeting · May 13, 2026”
“Elevance Health shareholders · elected · three directors · Gail K. Boudreaux, Robert L. Dixon, Jr., and Deanna D. Strable”
“Elevance Health shareholders · approved · executive compensation program · advisory basis”
“Elevance Health shareholders · ratified · Ernst & Young LLP · independent auditor for the 2026 fiscal year”
“Elevance Health shareholders · rejected · shareholder proposal · independent study on the impact of banning corporate contributions to partisan 527 political groups”
“most recent analyst rating on ELV stock · is · Hold · $360.00 price target”
